The Motley Fool

Stock market crash: Here are the stocks I’d buy if equities collapse in September

Image source: Getty Images.

Since the stock market crash in March, investors have been wondering if another one is imminent. The rebound in equity markets lately does not match with the economic fallout of the Covid-19 pandemic, and this is making shareholders nervous.

Stock market crash or correction

A market correction differs slightly from a crash. A crash is a dramatic decline of stock prices on a single day, whereas a correction is when a financial index falls over 10% below its most recent high and can last days, weeks, or months.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The European Union’s securities watchdog warns a sustained correction is likely. This is because recovery, and a bounce back to a pre-pandemic economy, is likely to take a very long time. The International Monetary Fund expects the eurozone GDP to fall over 10% this year, with slow recovery next year. For this reason, a September stock market crash is not out of the question, but I’m no psychic, so will have to wait and see. I think it’s best to prepare for every eventuality, and as a long-term value investor, keeping core principles in mind is a good place to start.

Dividend-paying stocks

I want to benefit from the power of dividend compounding and long-term growth. To do this I search for stocks that are likely to go the distance and make a sustained recovery from market lows. Companies falling into this category, in my view, include BAE Systems (LSE:BA), GlaxoSmithKline, and Royal Dutch Shell.

As geopolitical tensions rise and technology advances, cyber-crime is an increasing threat. This makes me think defence is a good sector to invest in. BAE Systems regularly wins international government contracts, and I think this will continue. Concern surrounding government defence spending has been suppressing the BAE share price in recent months, but in the long term I think spending will increase. The UK is already looking at ways to divert budgets to defence and intelligence, and other governments may follow suit.

BAE’s technological advancements are not only impressive but vital in ensuring high-calibre solutions for aerospace, defence, and security markets. Interpol recently released a report warning that cybercriminal activity has increased amid Covid-19. Russia and China have been accused of hacking, and fake news is on the rise. All this points to a need for continued investment in national security. BAE recently reinstated its dividend which has a yield of 4.5%. Earnings per share are 46.4p and its price-to-earnings ratio (P/E) is 11.

Diversified sectors

GlaxoSmithKline is a science-led pharmaceutical giant creating medicines and vaccines, including a Covid-19 vaccine in partnership with Sanofi. It’s a £75bn company that continues to pay a dividend with a current yield of 5.4%. Earnings per share for the trailing 12 months sit at £1.32 and, based on this, GSK’s P/E is 11.

Now, we all know renewables are the future of energy, but oil remains indispensable in reaching that eventuality. Royal Dutch Shell has been around for decades and I believe it has the knowledge, experience, and budgets to continue to profit and adapt in this changing environment. I think it’s a sensible long-term buy and at 4.6%, it offers a decent dividend yield.

There are many companies that have thrived since the last stock market crash and I would begin my research by looking to those as potential buys in the next one.

Are you looking to boost your portfolio with strong, resilient buys? Let us help you choose your stocks...

Did Boris Give This Stock a £50million+ Boost?

On February 3rd, 2020, Boris Johnson made a surprise announcement…

…potentially helping to grow one little-known British company’s revenues by an expected £50million+.

You probably saw this announcement in the news. But we bet you’ve never heard of the company which we believe could profit.

Get the full details here – while you have time.

Kirsteen owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.